HC Wainwright & Co. Maintains Buy on Pasithea Therapeutics, Raises Price Target to $4

Benzinga · 14h ago
HC Wainwright & Co. analyst Sara Nik maintains Pasithea Therapeutics (NASDAQ:KTTA) with a Buy and raises the price target from $3 to $4.